Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
20.30
-0.37 (-1.79%)
Aug 1, 2025, 11:18 AM - Market open

Company Description

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.

The company’s lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Dianthus Therapeutics, Inc.
Dianthus Therapeutics logo
CountryUnited States
Founded2015
IndustryBiotechnology
SectorHealthcare
Employees78
CEOMarino Garcia

Contact Details

Address:
7 Times Square, 43rd Floor
New York, New York 10036
United States
Phone929 999 4055
Websitedianthustx.com

Stock Details

Ticker SymbolDNTH
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001690585
CUSIP Number252828108
ISIN NumberUS2528281080
SIC Code2834

Key Executives

NamePosition
Marino Garcia M.B.A.President, Chief Executive Officer and Director
Ryan SavitzChief Financial Officer and Chief Business Officer
Simrat Randhawa M.B.A., M.D.Chief Medical Officer
Edward G. CarrChief Accounting Officer
Judson TaylorSenior Vice President and Head of Technical Operations
Jennifer Davis RuffVice President and Head of Investor Relations and Corporate Affairs.
Adam M. Veness Esq.Senior Vice President, General Counsel and Secretary
Kristina MaximenkoChief People Officer
Rashieda GluckHead of Clinical Development Operations
Scott Nogi M.B.A.Head of Business Operations

Latest SEC Filings

DateTypeTitle
May 22, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13GFiling
May 12, 202510-QQuarterly Report
May 12, 20258-KCurrent Report
May 12, 2025SCHEDULE 13G/AFiling
Apr 24, 2025SCHEDULE 13G/AFiling
Apr 17, 2025SCHEDULE 13GFiling
Apr 10, 2025ARSFiling